GlassScriptPhysician profile
Keri W Barr
NPI 1215300736
$34,586.65
in general payments reported to CMS, 2019-2025
15 companies · $5,249 in 2025
The $5,249 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,264 · 2022: $2,272 · 2023: $8,364 · 2024: $17K · 2025: $5,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $2,679 · Food and Beverage: $2,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,744.50 |
| Travel and Lodging | $2,678.61 |
| Food and Beverage | $2,628.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $30,327.72 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,103.28 | 2021-2024 | Caplyta |
| Alkermes, INC. | $520.96 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $511.64 | 2022-2024 | Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $498.23 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $409.96 | 2021-2025 | Invega Sustenna, Spravato, Invega |
| Abbvie INC. | $369.78 | 2021-2025 | |
| Lundbeck LLC | $275.01 | 2021-2025 | Rexulti |
| Corium, LLC | $225.61 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $132.88 | 2021-2022 | |
| Indivior INC. | $59.35 | 2022-2023 | Perseris |
| Axsome Therapeutics, INC. | $49.86 | 2022-2025 | Auvelity |
| Lilly USA, LLC | $46.38 | 2025 | Kisunla |
| Supernus Pharmaceuticals, INC. | $34.06 | 2022-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $21.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.